Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Clinical Rheumatology

• Publication date

  2013-07-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10067-013-2336-xPMID 23887439
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Patients non-responding to etanercept obtain lower etanercept concentrations compared to responding patients

  2013cited by this paper
• Immunogenicity of biological therapeutics: from assay to patient

  2012cited by this paper
• Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner

  2012cited by this paper
• Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients

  2011cited by this paper
• Advances in rheumatology: new targeted therapeutics

  2011cited by this paper
• Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis.

  2011cited by this paper
• Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases

  2011cited by this paper
• Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up.

  2011cited by this paper
• Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study.

  2011cited by this paper
• Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort study

  2011cited by this paper
• The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review

  2010cited by this paper
• The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept

  2010cited by this paper
• Dealing with immunogenicity of biologicals: assessment and clinical relevance

  2009cited by this paper
• Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study

  2009cited by this paper
• Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement.

  2008cited by this paper
• Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis

  2008cited by this paper
• Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis

  2008cited by this paper
• Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial.

  2008influential reference
• ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis

  2008cited by this paper
• Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis

  2007cited by this paper
• The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis.

  2007cited by this paper
• Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis

  2006cited by this paper
• Formation, Distribution, and Elimination of Infliximab and Anti-Infliximab Immune Complexes in Cynomolgus Monkeys

  2005cited by this paper
• B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab.

  2004cited by this paper
• Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.

  2004cited by this paper
• L’immunisation contre l’infliximab, associée à des réactions d’intolérance et à une perte d’efficacité, peut être prévenue par l’utilisation d’immunosuppresseurs

  2004cited by this paper
• Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.

  2003cited by this paper
• Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria.

  1996cited by this paper
• Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

  1995cited by this paper
• A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index.

  1994cited by this paper

• Ultra-sensitive diagnostic platform utilizing gold nanoparticle integrated in a freestanding hydrogel matrix.

  2026cites this paper
• Anti-emicizumab antibodies and their relevance in clinical practice

  2025cites this paper
• Serum metabolic signatures are associated with anti-drug antibody development in rheumatoid arthritis patients treated with adalimumab

  2025cites this paper
• Impact Of Immunomodulating Medication On Maternal Tdap Vaccination Induced Antibodies In Infants.

  2025cites this paper
• Infant ustekinumab Clearance, Risk of Infection, and Development after exposure during pregnancy.

  2024cites this paper
• Unique challenges required reassessment and alterations to critical reagents to rescue a neutralizing antibody assay.

  2024cites this paper
• Anti-tumor necrosis factor (aTNF) weaning strategy in juvenile idiopathic arthritis (JIA): does duration matter?

  2024cites this paper
• Anti-Drug-Antikörper und der Einfluss von Methotrexat und Biologika-Applikationsintervall

  2024cites this paper
• Validation of the pharmacokinetic model for anti- TNFα clearance in infants exposed to anti- TNFα during pregnancy.

  2023cites this paper
• Difficult to treat psoriatic arthritis — how should we manage?

  2023cites this paper
• The FDA’s New Guideline “Generally Accepted Scientific Knowledge” (GASK): An Opportunity to Expedite the Approval of Biosimilars

  2023cites this paper
• Biosimilars in the treatment of rheumatoid arthritis: a pharmacokinetic overview

  2023cites this paper
• Impact of methotrexate treatment on vaccines immunogenicity in adult rheumatological patients - Lessons learned from the COVID-19 pandemic.

  2023cites this paper
• Anti-drug antibodies of IL-17 inhibitors for psoriasis: a systematic review

  2022cites this paper
• Do genetics contribute to TNF inhibitor response prediction in Psoriatic Arthritis?

  2022cites this paper
• A2M inhibits inflammatory mediators of chondrocytes by blocking IL‐1β/NF‐κB pathway

  2022cites this paper
• Effectiveness and drug retention of biologic disease modifying antirheumatic drugs in Korean patients with late onset ankylosing spondylitis

  2021cites this paper
• Enzyme Therapy: Current Challenges and Future Perspectives

  2021cites this paper
• Achieving efficacy in subjects with sustained pegvaliase-neutralizing antibody responses.

  2021cites this paper
• Response to Vaccination in Infants Exposed to Antitumor Necrosis Factor Alpha In Utero

  2021cites this paper
• Recombinant Anti-idiotypic Antibodies in Ligand Binding Assays for Antibody Drug Development.

  2021cites this paper
• Low immunogenicity of emicizumab in persons with haemophilia A

  2021cites this paper
• Systematic Review and Principal Components Analysis of the Immunogenicity of Adalimumab

  2020cites this paper
• Head-to-Head Comparison of Etanercept vs. Adalimumab in the Treatment of Ankylosing Spondylitis: An Open-Label Randomized Controlled Crossover Clinical Trial

  2020cites this paper
• An update on serum biomarkers to assess axial spondyloarthritis and to guide treatment decision

  2020cites this paper
• T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation–Updated Consensus and Review 2020

  2020cites this paper
• Trigger-responsive engineered-nanocarriers and image-guided theranostics for rheumatoid arthritis.

  2020cites this paper
• Immunogenicity of Protein Therapeutics: A Lymph Node Perspective

  2020cites this paper
• 10th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals

  2020cites this paper
• A Roadmap for the Molecular Farming of Viral Glycoprotein Vaccines: Engineering Glycosylation and Glycosylation-Directed Folding

  2020cites this paper
• Drug levels and antibodies against TNF-blockers in spondyloarthritis and rheumatoid arthritis are associated with the activity but they do not predict it.

  2019cites this paper
• Etanercept With IVIg for Acute Kawasaki Disease: A Randomized Controlled Trial

  2019cites this paper
• Improved monovalent TNF receptor 1-selective inhibitor with novel heterodimerizing Fc

  2019cites this paper
• Effective serum level of etanercept biosimilar and effect of antidrug antibodies on drug levels and clinical efficacy in Chinese patients with ankylosing spondylitis

  2019cites this paper
• Pharmacotherapeutic strategies for standard treatment-resistant psoriasis

  2019cites this paper
• Early supplemental α2‐macroglobulin attenuates cartilage and bone damage by inhibiting inflammation in collagen II‐induced arthritis model

  2019cites this paper
• In-clinic experience with half dose Etanercept Biosimilar in Indian patients with rheumatic diseases: A single center observational study

  2019cites this paper
• Evaluation von Immunoassays zum Nachweis von Anti-Drug Antikörpern gegen Infliximab und korrespondierenden Infliximab Serumspiegeln bei Spondyloarthritis im klinischen Alltag

  2019cites this paper
• Recommendations for the Development and Validation of Immunogenicity Assays in Support of Biosimilar Programs

  2019cites this paper
• Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study

  2019cites this paper
• Anti-adalimumab antibodies kinetics: an early guide for juvenile idiopathic arthritis (JIA) switching

  2019cites this paper
• Immune-phenotyping of B cells unsing LEGENDScreen™ to investigate the role of B cells in immunogenicity, and immune regulation by Bregs, in patients with Rheumatoid Arthritis

  2019cites this paper
• Therapeutic drug monitoring of infliximab in spondyloarthritis. A review of the literature

  2019cites this paper
• Nonclinical immunogenicity risk assessment of therapeutic proteins.

  2019cites this paper
• Low Percentage of Signal Regulatory Protein α/β+ Memory B Cells in Blood Predicts Development of Anti-drug Antibodies (ADA) in Adalimumab-Treated Rheumatoid Arthritis Patients

  2018cites this paper
• Update upon efficacy and safety of etanercept for the treatment of spondyloarthritis and juvenile idiopathic arthritis

  2018cites this paper
• The comparative immunogenicity of biologic therapy and its clinical relevance in psoriatic arthritis: a systematic review of the literature

  2018cites this paper
• Immunoassay methods used in clinical studies for the detection of anti‐drug antibodies to adalimumab and infliximab

  2018cites this paper
• Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies

  2018cites this paper
• IL-6 is an independent predictive factor of drug survival after dose escalation of infliximab in patients with rheumatoid arthritis

  2018cites this paper
• Monovalent TNF receptor 1-selective antibody with improved affinity and neutralizing activity

  2018cites this paper
• Generation by phage display and characterization of drug-target complex-specific antibodies for pharmacokinetic analysis of biotherapeutics

  2018cites this paper
• Harnessing Apoptotic Cell Clearance to Treat Autoimmune Arthritis

  2017cites this paper
• Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Spondyloarthritis

  2017cites this paper
• Comparing Originator Biologics and Biosimilars: A Review of the Relevant Issues.

  2017cites this paper
• Recommendations for the Development and Validation of Neutralizing Antibody Assays in Support of Biosimilar Assessment

  2017cites this paper
• Gene Expression of Tumor Necrosis Factor-Alpha in Etanercept-Treated Rheumatoid Arthritis Patients

  2017cites this paper
• Detection of adalimumab and anti-adalimumab antibodies in patients with rheumatoid arthritis: a comprehensive overview of methodology pitfalls and benefits

  2017cites this paper
• Biologic therapies in rheumatic diseases: drug and anti-drug antibody levels and clinical efficacy

  2017influential citation
• Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence

  2017influential citation
• The impact of immunogenicity of TNFα inhibitors in autoimmune inflammatory disease. A systematic review and meta-analysis.

  2017cites this paper
• Intrapatient Variability in the Pharmacokinetics of Etanercept Maintenance Treatment

  2017cites this paper
• Spotlight on Anti‐CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date

  2017cites this paper
• Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review

  2017cites this paper
• Apoptotic cell infusion treats ongoing collagen-induced arthritis, even in the presence of methotrexate, and is synergic with anti-TNF therapy

  2016cites this paper
• Long-Term Safety and Efficacy of Subcutaneously Administered Tocilizumab for Adult Rheumatoid Arthritis: A Multicenter Phase 3b Long-term Extension Study

  2016cites this paper
• Leitthema: Meilensteine in der Rheumatologie: 75 Bände Innovation

  2016cites this paper
• Anti-Drug Antibodies, Drug Levels, Interleukin-6 and Soluble TNF Receptors in Rheumatoid Arthritis Patients during the First 6 Months of Treatment with Adalimumab or Infliximab: A Descriptive Cohort Study

  2016cites this paper
• [Biologics].

  2016cites this paper
• Detection of adalimumab and anti-adalimumab antibodies in patients with rheumatoid arthritis: a comprehensive overview of methodology pitfalls and benefits

  2016cites this paper
• Positive correlation between etanercept concentration and the decrease in Psoriasis Area and Severity Index scale value

  2016cites this paper
• Monitoring Therapy Response of Experimental Arthritis with Radiolabeled Tracers Targeting Fibroblasts, Macrophages, or Integrin αvβ3

  2016cites this paper
• Progress in understanding and utilizing TNF-α inhibition for the treatment of psoriatic arthritis

  2016cites this paper
• Influence of anti-TNF immunogenicity on safety in rheumatic disease: a narrative review

  2016cites this paper
• Immunogenicity of anti-TNF biologic agents in the treatment of rheumatoid arthritis

  2016cites this paper
• An observational study of the real-life management of psoriasis patients treated with etanercept according to the new reimbursement criteria (in Belgium)

  2016cites this paper
• Treatment of psoriasis with biologic agents in Malta

  2016cites this paper
• Biologic Therapy in Inflammatory and Immunomediated Arthritis: Safety Profile.

  2016cites this paper
• Chemically Modified Interleukin-6 Aptamer Inhibits Development of Collagen-Induced Arthritis in Cynomolgus Monkeys

  2016cites this paper
• Biosimilars in rheumatology: current perspectives and lessons learnt

  2015cites this paper
• B cell epitopes on infliximab identified by oligopeptide microarray with unprocessed patient sera

  2015cites this paper
• Drug survival and causes of discontinuation of the first anti-TNF in ankylosing spondylitis compared with rheumatoid arthritis: analysis from BIOBADABRASIL

  2015cites this paper
• Burden of dose escalation with tumour necrosis factor inhibitors in rheumatoid arthritis: a systematic review of frequency and costs.

  2015cites this paper
• Predicting Hemagglutinin MHC-II Ligand Analogues in Anti-TNFα Biologics: Implications for Immunogenicity of Pharmaceutical Proteins

  2015cites this paper
• Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis

  2015cites this paper
• Influence of Immunogenicity on the Efficacy of Long-Term Treatment with TNFα Blockers in Rheumatoid Arthritis and Spondyloarthritis Patients

  2015cites this paper
• DC-Based Immunotherapy Combined with Low-Dose Methotrexate Effective in the Treatment of Advanced CIA in Mice

  2015cites this paper
• Clinical management algorithm of uveitis associated with juvenile idiopathic arthritis: interdisciplinary panel consensus

  2015cites this paper
• Systemic Antipsoriatic Combination Therapy with Fumaric Acid Esters for Plaque-Type Psoriasis: Report on 17 Cases

  2015cites this paper
• Management of Crohn’s disease in poor responders to adalimumab

  2014cites this paper
• Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritis.

  2014cites this paper
• Update on biologics in psoriasis

  2014cites this paper
• Practical application of acid dissociation in monitoring patients treated with adalimumab

  2014cites this paper
• Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease

  2014cites this paper
• Distinct Effects of Methotrexate and Etanercept on the B Cell Compartment in Patients With Juvenile Idiopathic Arthritis

  2014cites this paper
• Etanercept biosimilars

  2014cites this paper
• Extent and consequences of antibody formation against adalimumab in patients with psoriasis: one-year follow-up.

  2014cites this paper
• Specific therapy to regulate inflammation in rheumatoid arthritis: molecular aspects.

  2014cites this paper
• Immunogenicity - implications for rheumatoid arthritis treatment.

  2013cites this paper
• Европейский конгресс ревматологов (Мадрид, 12—15 июня 2013 г. ) — проблемы ревматоидного артрита

  2013cites this paper